Results of the CAPRISA 012c clinical trial of a combination of two broadly neutralizing antibodies to prevent HIV infection in young women in southern Africa announced at IAS in Rio de Janeiro
We use cookies to make your experience with us better. By continuing to use our website, you are agreeing to our use of cookies. To find out more see our privacy policy.